Imidazodiazepines
Abstract
Abstract This invention is directed toward pharmacologically active compound of the formula <IMAGE> R1 is selected from the group consisting of hydrogen, lower alkyl, hydroxy lower alkyl, acyloxy lower alkyl, phenyl, alkoxy lower alkyl, halo lower alkyl, amino lower alkyl, substituted amino lower alkyl, substituted phenyl, pyridyl, aralkyl and the groups <IMAGE> wherein R is hydrogen or lower alkyl and ROOC where R is lower alkyl; R2 is selected from the group consisting of hydrogen, lower alkyl, hydroxy lower alkyl, acyloxy lower alkyl, alkoxy lower alkyl, halo lower alkyl, amino or substituted amino lower alkyl, amino, cyano, cyano lower alkyl, substituted amino, chloro, bromo and iodo, the group-COOR where R is hydrogen or lower alkyl, the group <IMAGE> where R is hydrogen or lower alkyl, or derivatives thereof, e.g., the group R-C=N-R' wherein R' is hydrogen, lower alkyl, hydroxy, phenyl, alkoxy, amino, mono or di-alkylamino and arylamino and R is hydrogen or lower alkyl, the group <IMAGE> (where R and R' are individually hydrogen, lower alkyl, hydroxy lower alkyl, lower alkenyl, aryl or together R and R' form a part of a heterocyclic ring and the group (CH2)n NRR' where R and R' are hydrogen, lower alkyl, hydroxy lower alkyl, lower alkenyl or together R and R' form a part of a heterocyclic ring and n is 1 to 4); the group <IMAGE> where R10, R11, R12 are hydrogen or lower alkyl and the group (CH2)n NR13R14 where n is 1 to 4 and R13, R14 are hydrogen, lower alkyl, hydroxy lower alkyl, lower alkenyl or R13 and R14 together form part of a heterocyclic ring, with the limitation that where R10, R11 or R12 is a basic side chain, then the remaining substituents are hydrogen or lower alkyl; X is a leaving group selected from the group consisting of halogen and alkyl or aryl sulfonate. R4 is selected from the group consisting of hydrogen, halogen, nitro, cyano, trifluoromethyl, lower alkyl, substituted amino, amino, hydroxy lower alkyl and lower alkanoyl; R6 is selected from the group consisting of phenyl, mono-substituted phenyl, di-substituted phenyl, pyridyl and mono-substituted pyridyl; and <IMAGE> is selected from the group consisting of <IMAGE> +TR <IMAGE> and the pharmaceutically acceptable salts thereof. Also provided are methods for the preparation of these compounds as well as pharmaceutical formulations which contain the active compounds of this invention. The compounds of the formulas illustrated above and their analogs are useful as anticonvulsants, muscle relaxants, anxiolytic and sedative agents.
Inventors
- 👤 Armin Walser
- 👤 Rodney I. Fryer
Bibliographic Details
Claims Analysis
Total Claims: 3References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1985-08-30 | 1986-03-01 | 1986-08-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1989-08-30 | 1990-03-01 | 1990-08-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1993-08-30 | 1994-03-01 | 1994-08-31 | $7700.00 | Window Closed / Lapsed |